ALXN1920

DRUG3 trials

Sponsors

Alexion Pharmaceuticals Inc., Alexion Pharmaceuticals, Inc.

Conditions

Healthy ParticipantsPrimary Mebranous Nephropathy (PMN)Primary Membranous Nephropathy

Phase 1

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants

CompletedNCT05751642

Alexion Pharmaceuticals, Inc.Healthy Participants

Start: 2023-04-19End: 2023-12-04Updated: 2024-11-27

Phase 2

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

RecruitingNCT07157787

Alexion Pharmaceuticals, Inc.Primary Membranous Nephropathy

Start: 2025-09-19End: 2027-07-09Target: 30Updated: 2026-06-18

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1920 in Adult Participants with PMN (Primary Membranous Nephropathy) who are at a High Risk for Disease Progression (AUTUMN)

RecruitingCTIS2025-520780-40-00

Alexion Pharmaceuticals Inc.Primary Mebranous Nephropathy (PMN)

Start: 2025-11-26Target: 9Updated: 2026-01-26